Endocrinology and hormone therapy in breast cancer: aromatase inhibitors versus antioestrogens.

2.50
Hdl Handle:
http://hdl.handle.net/10541/77878
Title:
Endocrinology and hormone therapy in breast cancer: aromatase inhibitors versus antioestrogens.
Authors:
Howell, Anthony ( 0000-0002-3879-5991 ) ; Dowsett, Mitch
Abstract:
Endocrine therapies act by either blocking or downregulating the oestrogen receptor or by reducing oestrogen concentrations around and within the cancer cell. In postmenopausal women, oestrogen suppression is achieved by inhibition of the enzyme aromatase by aromatase inhibitors (AIs). Modern AIs (anastrozole, letrozole and exemestane) are more potent than earlier ones and suppress oestradiol levels in plasma to virtually undetectable concentrations. Recent comparisons of AIs with the most widely used oestrogen receptor blocking drug tamoxifen indicate that, in general, AIs result in increased response rates and greater durations of response. Here, we summarize data supporting the difference between the two types of treatment and attempt to account for the underlying mechanisms that favour AIs.
Affiliation:
CRUK Department of Medical Oncology, University of Manchester, Christie Hospital, Manchester, UK. maria.parker@christie-tr.nwest.nhs.uk
Citation:
Endocrinology and hormone therapy in breast cancer: aromatase inhibitors versus antioestrogens. 2004, 6 (6):269-74 Breast Cancer Res.
Journal:
Breast Cancer Research
Issue Date:
2004
URI:
http://hdl.handle.net/10541/77878
DOI:
10.1186/bcr945
PubMed ID:
15535858
Type:
Article
Language:
en
ISSN:
1465-542X
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorHowell, Anthony-
dc.contributor.authorDowsett, Mitch-
dc.date.accessioned2009-08-19T14:33:11Z-
dc.date.available2009-08-19T14:33:11Z-
dc.date.issued2004-
dc.identifier.citationEndocrinology and hormone therapy in breast cancer: aromatase inhibitors versus antioestrogens. 2004, 6 (6):269-74 Breast Cancer Res.en
dc.identifier.issn1465-542X-
dc.identifier.pmid15535858-
dc.identifier.doi10.1186/bcr945-
dc.identifier.urihttp://hdl.handle.net/10541/77878-
dc.description.abstractEndocrine therapies act by either blocking or downregulating the oestrogen receptor or by reducing oestrogen concentrations around and within the cancer cell. In postmenopausal women, oestrogen suppression is achieved by inhibition of the enzyme aromatase by aromatase inhibitors (AIs). Modern AIs (anastrozole, letrozole and exemestane) are more potent than earlier ones and suppress oestradiol levels in plasma to virtually undetectable concentrations. Recent comparisons of AIs with the most widely used oestrogen receptor blocking drug tamoxifen indicate that, in general, AIs result in increased response rates and greater durations of response. Here, we summarize data supporting the difference between the two types of treatment and attempt to account for the underlying mechanisms that favour AIs.en
dc.language.isoenen
dc.subjectBreast Canceren
dc.subject.meshAnimals-
dc.subject.meshAntineoplastic Agents, Hormonal-
dc.subject.meshAromatase Inhibitors-
dc.subject.meshBreast Neoplasms-
dc.subject.meshEstrogen Receptor Modulators-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshRandomized Controlled Trials as Topic-
dc.subject.meshTamoxifen-
dc.titleEndocrinology and hormone therapy in breast cancer: aromatase inhibitors versus antioestrogens.en
dc.typeArticleen
dc.contributor.departmentCRUK Department of Medical Oncology, University of Manchester, Christie Hospital, Manchester, UK. maria.parker@christie-tr.nwest.nhs.uken
dc.identifier.journalBreast Cancer Researchen
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.